IRIS
LAPADULA, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.775
AS - Asia 5.444
EU - Europa 4.879
SA - Sud America 1.545
AF - Africa 197
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 9
Totale 27.861
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.580
SG - Singapore 2.337
IT - Italia 1.404
CN - Cina 1.258
BR - Brasile 1.208
SE - Svezia 714
HK - Hong Kong 674
FR - Francia 662
RU - Federazione Russa 527
DE - Germania 482
VN - Vietnam 375
FI - Finlandia 312
GB - Regno Unito 264
UA - Ucraina 195
IN - India 167
BD - Bangladesh 132
AR - Argentina 127
IQ - Iraq 86
CA - Canada 85
BE - Belgio 62
MX - Messico 60
ID - Indonesia 56
IE - Irlanda 52
PK - Pakistan 51
ZA - Sudafrica 51
TR - Turchia 49
EC - Ecuador 47
CO - Colombia 45
SA - Arabia Saudita 36
ES - Italia 35
JP - Giappone 35
VE - Venezuela 33
MA - Marocco 30
CI - Costa d'Avorio 27
PL - Polonia 25
UZ - Uzbekistan 24
CL - Cile 23
NL - Olanda 23
PY - Paraguay 23
AT - Austria 21
EG - Egitto 21
PH - Filippine 21
IR - Iran 18
TN - Tunisia 18
CZ - Repubblica Ceca 16
LT - Lituania 16
AZ - Azerbaigian 15
JM - Giamaica 15
PE - Perù 13
KE - Kenya 12
UY - Uruguay 12
NP - Nepal 10
AE - Emirati Arabi Uniti 9
BO - Bolivia 9
DZ - Algeria 9
ET - Etiopia 9
JO - Giordania 9
MY - Malesia 9
EU - Europa 8
OM - Oman 8
DK - Danimarca 7
AL - Albania 6
AU - Australia 6
IL - Israele 6
NI - Nicaragua 6
RS - Serbia 6
TH - Thailandia 6
BY - Bielorussia 5
CH - Svizzera 5
CR - Costa Rica 5
HN - Honduras 5
HR - Croazia 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LB - Libano 5
PA - Panama 5
QA - Qatar 5
RO - Romania 5
AO - Angola 4
BG - Bulgaria 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
MD - Moldavia 4
MN - Mongolia 4
PS - Palestinian Territory 4
PT - Portogallo 4
SY - Repubblica araba siriana 4
BH - Bahrain 3
GE - Georgia 3
GF - Guiana Francese 3
GR - Grecia 3
KR - Corea 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
DM - Dominica 2
EE - Estonia 2
GY - Guiana 2
Totale 27.823
Salva come PNG Salva come JPEG
Città #
Fairfield 1.879
Woodbridge 1.473
Ashburn 1.404
Singapore 1.261
Houston 1.193
Chandler 1.067
Seattle 798
Ann Arbor 748
San Jose 725
Cambridge 683
Hong Kong 670
Milan 618
Wilmington 607
Nyköping 550
Jacksonville 539
Beijing 361
Lawrence 245
Roxbury 245
Nanjing 225
Dallas 224
Lauterbourg 222
New York 203
Rome 198
Des Moines 149
Inglewood 145
Los Angeles 142
Princeton 136
Ho Chi Minh City 111
Munich 108
Santa Clara 105
São Paulo 103
Boardman 101
Bari 97
San Diego 88
Helsinki 84
Dearborn 81
Hanoi 78
London 70
Shenyang 65
Brussels 62
Moscow 62
Brooklyn 61
Columbus 59
Figino 56
Paris 55
Buffalo 54
Dublin 51
Hebei 50
Nanchang 44
Rio de Janeiro 42
Turku 42
Council Bluffs 41
Chicago 39
Jiaxing 39
Baghdad 38
Redwood City 35
Tokyo 33
Changsha 32
Frankfurt am Main 32
Belo Horizonte 31
The Dalles 31
Tianjin 31
Turin 30
Bar Harbor 29
Jakarta 29
Boston 28
San Francisco 28
Abidjan 26
Falkenstein 26
Nuremberg 26
Toronto 25
Montreal 24
Orem 24
Atlanta 23
Brasília 23
Denver 23
Dong Ket 23
Guangzhou 23
Lahore 23
Tashkent 23
Warsaw 23
Dhaka 20
Johannesburg 20
Campinas 19
Quito 19
Da Nang 18
Hefei 18
Chennai 17
Poplar 17
Augusta 16
Guayaquil 16
Jinan 16
Mumbai 16
Jeddah 15
Naples 15
Shanghai 15
Stockholm 15
Baku 14
Haiphong 14
Manchester 14
Totale 19.614
Salva come PNG Salva come JPEG
Nome #
Safety of Long-Term Biologic Therapy in Rheumatologic Patients With a Previously Resolved Hepatitis B Viral Infection 208
Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors 207
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 198
No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan 194
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease 192
A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab 187
AB0618 A unique ultrasound pattern of adipose tissue in systemic sclerosis patients: a comparison with rheumatoid arthritis patients and healthy controls. two sides of adipose tissue involvement in systemic chronic inflammatory diseases 185
AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease 185
Adalimumab in the treatment of immune-mediated diseases 181
A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy 179
AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1 178
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease 177
Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients 177
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 176
Early changes of articular cartilage, synovial membrane and subchondral bone in an experimental model of goat osteoarthrtitis 172
Retinal vessels thrombosis as onset manifestation of systemic sclerosis: 3 clinical cases 172
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study 171
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives 170
Papular-purpuric gloves and socks syndrome due to parvovirus B19: a report of two simultaneous cases in cohabitant families 169
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: Premises, perils, and perspectives 168
Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies 168
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 167
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature 165
Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA 165
SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings 164
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register 163
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis 162
Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis 161
Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy 161
Orofacial Manifestations and Temporomandibular Disorders of Sjogren Syndrome: An Observational Study 160
Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response 155
Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab 155
Leucocytoclastic vasculitis as onset symptom of ulcerative colitis 154
ANTI-TNFA THERAPY IN PSORIATIC ARTHRITIS: DIFFERENT RATE OF REMISSION IN POLYARTICULAR AND OLIGOARTICULAR SUBSETS 154
Orofacial Manifestations and Temporomandibular Disorders of Systemic Scleroderma: An Observational Study. 153
Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life 152
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study 150
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 147
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine 147
Old and new antirheumatic drugs and the risk of hepatotoxicity 147
AN UNWELCOME HOST IN THE PATHOGENESIS OF ARTHRITIDES 146
SAT0212 Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines 146
Intra-articular therapy with tumor necrosis factor-α antagonists: An update 143
Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features 143
Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study 143
Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis 143
Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa 142
Serum cartilage oligomeric matrix protein (COMP) following infliximab treatment in patients with rheumatoid arthritis: Analitical performances and clinical correlations 142
ASSOCIATION OF SYSTEMIC SCLEROSIS AND PSORIATIC ARTHRITIS: A CASE REPORT 141
Serum amyloid-A in Behçet's disease 141
LIPID PROFILE OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ANTI-TNF-ALPHA DRUGS CHANGES ACCORDING TO DISEASE ACTIVITY RESPONSE 141
Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings 140
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 139
Analysis of subchondral cortical plate and trabecular bone in osteoarthritis experimentally induced in goat tibia. Preliminary results 138
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper 138
PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists 138
PRESENT STATUS AND NEW PERSPECTIVES IN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS THERAPY 138
Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab 137
Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: A multicenter randomized clinical trial 136
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register 135
FRI0110 Methotrexate monotherapy in real life: a drug survival analysis. comparison between very early arthritis and early arthritis cohorts 135
Management of Small Vessel Vasculitides 134
Untangling the web of systemic autoinflammatory diseases 132
Obesity and Inflammation – Targets for OA Therapy 131
Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature 131
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 131
Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis 131
Different joint and skin clinical response of patients with psoriatic arthritis treated with infliximab 130
Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: International recommendations 129
Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register) 129
AB0245 PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE) 129
OP0129 Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors 129
Update on the profile of the EUSTAR cohort: An analysis of the EULAR Scleroderma Trials and Research group database 128
Improvement of Refractory Dysphagia in Patients with Idiopathic Inflammatory Myopathies Receveing Immunoglobulin Intravenous Therapy 127
). Analysis of subchondral cortical plate and trabecular bone in osteoarthritis experimentally induced in goat tibia. Preliminary results. 126
Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA 126
Prevalence of anti-CCP antibodies in systemic sclerosis 126
ISOLATED STERNOCLAVICULAR JOINT ARTHRITIS IN HEROIN ADDICTS AND/OR HIV POSITIVE PATIENTS: THREE CASES 124
Digital laser doppler flowmetry may discriminate "limited" from "diffuse" systemic sclerosis 122
Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis 122
The pathophysiology of osteoarthritis 121
Giant Cell Tumor of Synovial Sheath: Of Two Cases Treated with Intra-Articular Infiltration of Infliximab 121
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 121
Isolated thrombocytopenia associated with low dose methotrexate therapy 120
Sarcoidosis presenting with Raynaud's syndrome: a case report 120
Anti-cyclic citrullinated peptide autoantibodies measured by an automated enzyme immunoassay: analytical performance and clinical correlations 120
Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies 120
EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR) 119
GISEA: an Italian biological agents registry in rheumatology 119
Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid 118
Efficacy and safety of certolizumab pegol in rheumatoid arthritis: Meeting rheumatologists' requirements in routine clinical practice 118
THU0168 Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis 118
Response of cartilage oligomeric matrix protein to monoclonal antibody drugs in patients with rheumatoid arthritis 116
MONOCLONAL ANTIBODY INVESTIGATION IN RHEUMATOID ARTHRITIS: PRESENCE OF A T CELL SUBPOPULATION BEARING A DOUBLE MARKER 115
CHONDROCYTES-ECM INTERACTIONS IN HUMAN OSTEOARTHRITIS In: Mallia C., Uitto J. (eds) Rheumaderm. Advances in Experimental Medicine and Biology, vol 455. Springer, Boston, MA 115
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE) 115
THE INHIBITOR OF COSTIMULATION OF T CELLS: ABATACEPT 114
A CASE OF SWEET'S SYNDROME WITH RHEUMATIC ONSET 112
PHENOTYPING OF CHONDROCYTES FROM HUMAN OSTEOARTHRITIC CARTILAGE: CHONDROCYTE EXPRESSION OF BETA INTEGRINS AND CORRELATION WITH ANATOMIC INJURY 112
Cutaneous lesions as presenting symptoms of primary biliary cirrhosis: an undifferentiated connective tissue disease-like onset 112
Totale 14.524
Salva come PNG Salva come JPEG
Categoria #
all - tutte 118.635
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 118.635
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.797 125 209 23 111 87 118 85 102 102 112 293 430
2022/20232.808 435 326 192 265 321 358 58 287 449 19 59 39
2023/2024758 77 174 32 55 49 176 17 43 3 33 12 87
2024/20253.723 63 65 342 103 56 311 275 391 165 216 576 1.160
2025/20268.281 1.138 384 472 969 918 454 944 271 716 714 185 1.116
2026/2027183 183 0 0 0 0 0 0 0 0 0 0 0
Totale 28.520